Cdk9 Antibody (F-6): sc-376646
- Cdk9 Antibody (F-6) is a mouse monoclonal IgG1 κ, cited in 3 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 343-372 at the C-terminus of Cdk9 of human origin
- recommended for detection of Cdk9 of mouse, rat and human origin by WB, IP, IF and ELISA; also reactive with additional species, including and equine, canine, bovine and porcine
- See Cdk9 (D-7): sc-13130 for Cdk9 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for Cdk9 Antibody (F-6) for WB applications. These reagents are now offered in bundles with Cdk9 Antibody (F-6) (see ordering information below).
Cdk9 Antibody (F-6) is a mouse monoclonal IgG1 kappa light chain antibody designed to target Cyclin-dependent kinase 9 (Cdk9), also known as PITALRE or CDC2L4. anti-Cdk9 antibody (F-6) specifically recognizes an epitope mapping between amino acids 343-372 at the C-terminus of the human Cdk9 protein, ensuring precise and reliable detection. Cdk9 is a pivotal member of the cyclin-dependent kinase family, characterized by its conserved kinase domain that facilitates ATP binding and substrate phosphorylation, which are essential for enzymatic activity. The structural integrity of Cdk9, particularly within its C-terminal region, is crucial for interaction with cyclin partners such as Cyclin T1, forming the positive transcription elongation factor b (P-TEFb) complex. This complex plays a vital role in regulating transcription elongation by phosphorylating the C-terminal domain of RNA polymerase II, thereby enabling the expression of genes involved in critical cellular processes like cell cycle progression, differentiation, and apoptosis. The structural domains of Cdk9 are integral to function, as they determine substrate specificity and regulatory mechanisms, making accurate detection of conformation and interactions essential for understanding roles in cellular homeostasis and disease pathology. Additionally, Cdk9 is involved in phosphorylating the retinoblastoma protein, linking to the control of cell cycle and cellular proliferation. Dysregulation of Cdk9 structure and function is associated with various diseases, including cancer and viral infections such as HIV, where Cdk9 is necessary for transcriptional activation mediated by HIV Tat protein. Cdk9 (F-6) antibody demonstrates broad species reactivity, effectively detecting Cdk9 from mouse, rat, and human origins through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA), and is also reactive with additional species including equine, canine, bovine, and porcine.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdk9 Antibody (F-6) | sc-376646 | 200 µg/ml | $322.00 | |||
Cdk9 Antibody (F-6): m-IgG Fc BP-HRP Bundle | sc-540622 | 200 µg Ab; 10 µg BP | $361.00 | |||
Cdk9 Antibody (F-6): m-IgG1 BP-HRP Bundle | sc-542253 | 200 µg Ab; 20 µg BP | $361.00 | |||
Cdk9 (F-6) Neutralizing Peptide | sc-376646 P | 100 µg/0.5 ml | $69.00 |